OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).

NCT Number	NCT07136012
Lead Sponsor	Amgen
Conditions	Cardiovascular Disease
Enrollment	11,000 participants
Start Date	2025-08-22
Primary Completion	2031-10-20 (estimated)
Study Completion	2031-10-20 (estimated)
Updated on ClinicalTrials.gov	2026-07-10